Etanercept Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2018 - 2026

Etanercept Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2018 - 2026

  • Transparency Market Research
  • Ongoing
  • Healthcare

Report Description


Etanercept is an injectable drug prescribed for the treatment of autoimmune diseases such as spondylitis and arthritis. Tumor necrosis factor (TNF alpha) is a protein manufactured during inflammation, the body’s response to injury. TNF alpha protein stimulates inflammation and related signs such as tenderness and swelling. Etanercept is a man-made protein that binds TNF cascade and prevents the TNF alpha from stimulating inflammatory factors. In November 1998, the U.S. Food and Drug Administration (FDA) approved etanercept. Research findings suggest that problems related to blood, immune system, seizures, and heart failure are some of the side effects associated with the usage of etanercept. However, these side effects vary from person to person.

Lifestyle diseases are those whose occurrence is based on the daily habits of people. Usually, these diseases occur due to unsuitable relationship between people and the environment. Some of the key elements adding to list of lifestyle diseases. According to a report published by the World Economic Forum and the World Health Organization, India has incurred loss in billions of dollars in the past few years due to faulty diet and unhealthy habits. Lifestyle diseases are increasing globally and nearly one-third of the global population is likely to suffer from these in the near future. Obesity also includes patients with inflammatory arthritis. According to the same report, around 62% of the global deaths during 2006–2011 resulted from non-communicable diseases, which accounted for 45% of premature deaths. It suggested that nearly 85% of deaths will occur in low and middle income countries such as India, Malaysia, Brazil, and China in the next few year due to increase in burden of nutritional deficiencies, perinatal conditions, poor material, and infectious diseases.

The global etanercept market is projected to grow at a rapid pace during the forecast period. This is attributed to increase in incidence of obesity, lifestyle disorders, accidents, and prevalence of spondylitis. Enbrel has witnessed significant demand compared to other therapeutic proteins. It is used in the treatment of auto-immune diseases such as juvenile rheumatoid arthritis, psoriasis, and plaque. Rise in prevalence of these diseases is expected to propel the global etanercept market. Additionally, technological advancements and research and development activities could present new opportunities in the global etanercept market. However, rise in cost of overall treatment, lack of reimbursement policies in developing nations, and side effects associated with the treatment are anticipated to restrain the global market.

The global etanercept market can be segmented based on product and application. In terms of product, the market can be divided into Enbrel and Benepali. Based on application, the global etanercept market can be classified into ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, juvenile idiopathic arthritis (JIA), and others.

Geographically, the global etanercept market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The market in North America is expected to grow at a rapid pace in the next few years. The region’s dominance of the global market is attributed to favorable reimbursement scenario, acceptance of advanced techniques, and technologically advanced health care system. Europe and Asia Pacific are the other major markets for etanercept. Presence of key players, increase in investments in research and development activities by major pharma players, and collaborations of pharma and biotech companies with research institutes drive the etanercept market in these regions.

Major players in the global etanercept market include Pfizer, Inc., Immunex Corporation, Celltrion, Inc., Novartis International AG, Samsung Bioepis Co., Ltd., GlaxoSmithKline Pharmaceuticals Ltd., F. Hoffmann-La Roche Ltd., Takeda Pharmaceutical Company Ltd., and Cipla Limited.

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

The study is a source of reliable data on:

  • Market segments and sub-segments
  • Market trends and dynamics
  • Supply and demand
  • Market size
  • Current trends/opportunities/challenges
  • Competitive landscape
  • Technological breakthroughs
  • Value chain and stakeholder analysis

The regional analysis covers:

  • North America (U.S. and Canada)
  • Latin America (Mexico, Brazil, Peru, Chile, and others)
  • Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, and Luxembourg)
  • Eastern Europe (Poland and Russia)
  • Asia Pacific (China, India, Japan, ASEAN, Australia, and New Zealand)
  • Middle East and Africa (GCC, Southern Africa, and North Africa)

The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industry’s value chain.

A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates is included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.

Highlights of the report:

  • A complete backdrop analysis, which includes an assessment of the parent market
  • Important changes in market dynamics
  • Market segmentation up to the second or third level
  • Historical, current, and projected size of the market from the standpoint of both value and volume
  • Reporting and evaluation of recent industry developments
  • Market shares and strategies of key players
  • Emerging niche segments and regional markets
  • An objective assessment of the trajectory of the market
  • Recommendations to companies for strengthening their foothold in the market   

Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis. 

Have query on this report?

Make an Enquiry

Success Stories

Our Clients